SCHEMBL1707161

SCHEMBL1707161

CC(=O)c1cccc(Cc2nc(C(=O)O)co2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
MAPT P10636 1/20 0.43
KLKB1 P03952 1/20 0.43
IL4I1 Q96RQ9 1/20 0.43
MAOB P27338 1/20 0.41
PIK3CG P48736 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPK1 P28482 1/20 0.39
CES1 P23141 1/20 0.39
PTGER1 P34995 1/20 0.39
SRC P12931 1/20 0.39
FOLH1 Q04609 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706806 0.88 IL4I1 (0.42) LMNAMAPTKLKB1IL4I1MAOB
SCHEMBL1706233 0.86 LOXL2 (0.44) LMNAMAPTKLKB1IL4I1MAOB
SCHEMBL27899551 0.82 IL4I1 (0.38) LMNAMAPTKLKB1IL4I1MAOB
SCHEMBL11910638 0.81 CES1 (0.50) KLKB1CES1PTGER1MEN1KMT2A
SCHEMBL28802129 0.81 LMNA (0.43) LMNAMAPTKLKB1IL4I1MAOB
SCHEMBL27912754 0.81 ALDH1A1 (0.46) MAPTKLKB1MRGPRX4MEN1KMT2A
SCHEMBL21333174 0.79 DAGLA (0.52) LMNAMAPTKLKB1SMN1; SMN2CES1
SCHEMBL11561288 0.78 SMN1; SMN2 (0.51) PIK3CGMRGPRX4SMN1; SMN2RAB9ARXFP1
SCHEMBL3335985 0.74 LMNA (0.59) LMNAIL4I1MAOBMRGPRX4MAPK1
SCHEMBL2872214 0.74 HDAC1 (0.52) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803237-B Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2014-09-24 CN disclosed
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
CN-102803237-A Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2012-11-28 CN disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 LMNA 3835/4885MAPT 3232/4885KLKB1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.